Center-Authored Papers

Filters: Author is Luznik, Leo  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, Jones RJ, Ambinder RF, Maris MB, Blume KG et al..  2008.  Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(11):1279-87. Abstract
C
Ciurea SO, Zhang M-J, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, Armand P, Antin JH, Chen J, Devine SM et al..  2015.  Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia.. Blood. Abstract
Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, van den Brink MRM, Hansen JA, Parkman R, Miklos DB et al..  2016.  The Biology of Chronic Graft-Versus-Host Disease: a Task Force Report From the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
K
Kanakry CG, Bolaños-Meade J, Kasamon YL, Zahurak M, Durakovic N, Furlong T, Mielcarek M, Medeot M, Gojo I, Smith DB et al..  2017.  Low immunosuppressive burden after HLA-matched related or unrelated BMT using post-transplantation cyclophosphamide.. Blood. Abstract
Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF et al..  2014.  Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(31):3497-505. Abstract
Kanakry CG, Bakoyannis G, Perkins SM, McCurdy SR, Vulic A, Warren EH, Daguindau E, Olmsted T, Mumaw C, Towlerton AMH et al..  2017.  Plasma-derived proteomic biomarkers in HLA-haploidentical or HLA-matched bone marrow transplantation using post-transplantation cyclophosphamide.. Haematologica. Abstract
Kanakry CG, Coffey DG, Towlerton AMH, Vulic A, Storer BE, Chou J, Yeung CCS, Gocke CD, Robins HS, O'Donnell PV et al..  2016.  Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide.. JCI insight. 1(5) Abstract
Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai H-L, Bolaños-Meade J, Morris LE, Crilley PA, O'Donnell PV, Rossiter N et al..  2010.  Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(4):482-9. Abstract
L
Luznik L, O'Donnell PV, Fuchs EJ.  2012.  Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.. Seminars in oncology. 39(6):683-93. Abstract
Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell SM, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF et al..  2008.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(6):641-50. Abstract
O
Orozco JJ, Kenoyer A, Balkin ER, Gooley TA, Hamlin DK, Wilbur SD, Hylarides MD, Frost SHL, Mawad R, O'Donnell P et al..  2015.  Anti-CD45 radioimmunotherapy without TBI before BMT facilitates persistent haploidentical donor engraftment in a murine model.. Blood. Abstract